Biotechnology Company Receives ''Overweight'' Rating From Investment Firm: 462% Upside

Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler underscores a growing confidence in Zura Bio's prospects, aligning with similar sentiments expressed by other market analysts. $Zura Bio (ZURA.US)$